Get the Stockscreener App
0.4305
1.25%
0.0053
After Hours:
.42
-0.0105
-2.44%
Bioatla Inc stock is traded at $0.4305, with a volume of 1.79M.
It is up +1.25% in the last 24 hours and down -47.74% over the past month.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
See More
Previous Close:
$0.4252
Open:
$0.4405
24h Volume:
1.79M
Relative Volume:
1.07
Market Cap:
$25.31M
Revenue:
-
Net Income/Loss:
$-123.46M
P/E Ratio:
-0.1662
EPS:
-2.59
Net Cash Flow:
$-104.11M
1W Performance:
-39.96%
1M Performance:
-47.74%
6M Performance:
+14.46%
1Y Performance:
-28.44%
1-Day Range:
$0.4047
$0.4729
1-Week Range:
$0.4047
$0.8192
52-Week Range:
$0.2601
$1.43
Bioatla Inc Stock (BCAB) Company Profile
Name
Bioatla Inc
Sector
Industry
Phone
858-558-0708
Address
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.4305 | 25.00M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Nov-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-22 | Initiated | JMP Securities | Mkt Outperform |
| May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-21-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Jun-28-21 | Initiated | ROTH Capital | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | BTIG Research | Buy |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | JP Morgan | Overweight |
| Jan-11-21 | Initiated | Jefferies | Buy |
View All
Bioatla Inc Stock (BCAB) Latest News
After-Hours Biotech Rally: Alumis, Genelux, Bright Minds, Context Therapeutics Post Big Gains - RTTNews
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Benzinga
BioAtla, GATC Health Advance Ozuriftamab Vedotin Into Phase 3 OPSCC Trial Via SPV Deal - Voice Of HealthCare
BioAtla Stock Slips Premarket After Early Pop As Investors Weigh $40M SPV Deal For Phase 3 Cancer Trial - Asianet Newsable
BioAtla stock slips premarket after early pop as investors weigh $40M SPV deal for phase 3 cancer trial - MSN
BioAtla’s Phase 3 Cancer Trial Is “AI-Backed”. Just Not in the Way You Think - AIM Media House
BioAtla and GATC Health to advance Oz-V in Phase III trial - Yahoo Finance
BioAtla announces $40 million oncology SPV investment deal - MSN
BioAtla secures $40 million for phase 3 cancer drug development By Investing.com - Investing.com Nigeria
Bioatla stock rises after $40 million SPV deal to advance cancer drug - Investing.com Australia
BioAtla (BCAB) Teams Up with GATC Health for $40M SPV Transaction to Tackle OPSCC with Oz-V - parameter.io
Bioatla stock rises after $40 million SPV deal to advance cancer drug By Investing.com - Investing.com South Africa
BioAtla Announces $40 Million Oncology SPV Investment Deal - TipRanks
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle Transaction to Advance Ozuriftamab Vedotin into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma - Investing News Network
BioAtla Signs Multiple Material Agreements - TradingView — Track All Markets
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) - The Manila Times
BioAtla secures $40 million for phase 3 cancer drug development - Investing.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
$40M AI-driven cancer deal backs new OPSCC drug into Phase 3 test - Stock Titan
BioAtla adjourns special meeting, stockholders approve share issuance By Investing.com - Investing.com Australia
BioAtla Stockholders Approve Share Issuance, Delay Reverse Split - TipRanks
BioAtla adjourns special meeting, stockholders approve share issuance - Investing.com
BioAtla stockholders approve share issuance, delay reverse split - MSN
BioAtla, Inc. (NASDAQ:BCAB) Sees Significant Drop in Short Interest - Defense World
Can BioAtla Inc. stock reach $100 price targetGap Up & Safe Swing Trade Setup Alerts - Улправда
Aug Drivers: Why retail investors pile into BioAtla Inc. stockInsider Selling & Weekly Watchlist of Top Performers - Улправда
How BioAtla Inc. stock performs in rising dollar environmentWeekly Trade Analysis & Technical Confirmation Trade Alerts - Улправда
Why retail investors pile into BioAtla Inc. stockTrade Volume Report & Technical Pattern Alert System - Улправда
How rising interest rates impact BioAtla Inc. stock2025 Bull vs Bear & Weekly Momentum Stock Picks - DonanımHaber
Can BioAtla Inc. stock rebound after recent weakness2025 Analyst Calls & Verified Stock Trade Ideas - Улправда
Can BioAtla Inc. stock resist market sell offsEarnings Overview Report & Daily Entry Point Alerts - Улправда
BioAtla Earnings Notes - Trefis
Acorn Capital Advisors LLC Has $1.92 Million Stock Holdings in BioAtla, Inc. $BCAB - Defense World
What drives BioAtla Inc stock priceIndustrial Stocks Review & Exceptional Capital Trading - earlytimes.in
Taking on analysts’ expectations and winning: BioAtla Inc (BCAB) - setenews.com
BioAtla (NASDAQ: BCAB) seeks approval for stock issuance and reverse split - Stock Titan
Is BioAtla Inc. stock positioned well for digital economyTrade Risk Report & Safe Entry Trade Signal Reports - Newser
Will BioAtla Inc. stock continue dividend increasesJuly 2025 Levels & Stepwise Entry and Exit Trade Signals - Newser
Why BioAtla Inc. stock is considered a top pickDollar Strength & High Return Trade Opportunity Guides - Newser
CFO Waldron Surrenders 2,371 Of BioAtla Inc [BCAB] - TradingView — Track All Markets
Officer Vasquez Surrenders 1,566 Of BioAtla Inc [BCAB] - TradingView — Track All Markets
Biotech Momentum Builds In After-Hours Trading As BioAtla, Entero, And Sonnet Climb - Nasdaq
Bioatla Inc Stock (BCAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):